Billionaire Elon Musk posted on social media late Monday that his brain-computer interface company Neuralink implanted an experimental device into a human brain for the first time on Sunday.
according to Posted by Mr. Mask, which appeared on the platform formerly known as Twitter, said the recipient was “recovering well” and the first 24-hour results showed “promising detection of neuronal spikes.” Neuralink implanted a device in a person called telepathy that aims to allow the user to control devices such as phones and computers just by thinking.
The transplant comes about eight months after the company announced that the Food and Drug Administration had finally given it the long-awaited approval to begin its first human trials. Recruitment for the trial began in September. Musk had claimed trials would begin as early as 2020, but the FDA reportedly cited a list of dozens of “deficiencies” and safety concerns that Neuralink had yet to address. It is reported that it was submitted to the government and refused approval in 2022.
according to Pamphlet Neuralink’s trial, which is listed on the company’s website, is called the PRIME (Precision Robotic Implantable Brain Computer Interface) study, which involves brain computer interface implants; , is designed to test both the surgical robots the company uses to delicately implant devices directly into brain tissue. Intention of movement. People eligible to volunteer included people who had lost function in all four limbs due to spinal cord injury or amyotrophic lateral sclerosis (ALS).
Neuralink did not immediately respond to Ars’ request for comment. At the time of publication, the company had not released any news or information regarding the progress of the trial or the first human recipient. Additionally, the company does not yet appear to have registered any clinical trials with the federal Clinical Trials Registry (clinicaltrials.gov). However, it reposted Musk’s Monday post on its social media accounts.
Neuralink’s first human transplant came after a series of problems and federal scrutiny, as well as a delayed start to clinical trials. The company is reportedly under federal investigation for alleged animal abuse, including “hacking” surgeries by current and former Neuralink employees; Needless suffering and death of pigs and monkeys. Reuters reported last week that the company was fined for violating U.S. Department of Transportation (DoT) regulations. Moving dangerous goods, contains xylene, a toxic and flammable solvent sometimes used to process tissues. Despite progress in clinical trials, Neuralink is still considered to be far behind competitors such as Blackrock Neurotech, which has years of clinical research under its belt.
